You are now leaving the pages of www.gilead.com intended for U.S. audiences. The information in this section is intended for visitors outside the United States.
John F. Milligan, PhD, Reassumes Role of Chief Financial Officer
FOSTER CITY, Calif.--(BUSINESS WIRE)--Jan. 21, 2008--Gilead Sciences, Inc. (Nasdaq:GILD) today announced that Caroline Dorsa has resigned from her position as Chief Financial Officer (CFO), a role she assumed in November 2007, to pursue another opportunity.
Gilead plans to initiate a search to identify a new CFO. In the interim, John F. Milligan, PhD, Gilead's Chief Operating Officer, will reassume the additional responsibilities of CFO - a position he held from 2003 until 2007 - effective immediately.
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.
For more information on Gilead, please call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235) or visit www.gilead.com.
CONTACT: Gilead Sciences, Inc. Susan Hubbard, 650-522-5715 (Investors) Amy Flood, 650-522-5643 (Media) SOURCE: Gilead Sciences, Inc.